Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On September 2, 2025, Dr. Reddy’s Laboratories announced its participation in an upcoming investor conference organized by Investec, scheduled for September 5, 2025. The meeting will be conducted virtually and will involve group discussions with institutional investors, reflecting the company’s ongoing engagement with its stakeholders and efforts to maintain transparency in its operations.
The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, particularly in biosimilars and environmental leadership. However, challenges in the U.S. generics market and regulatory issues temper the outlook. The technical indicators suggest a neutral trend, and the valuation appears fair.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and manufacturing of generic medications, active pharmaceutical ingredients, and over-the-counter products, serving a global market with a focus on affordable healthcare solutions.
Average Trading Volume: 1,443,634
Technical Sentiment Signal: Buy
Current Market Cap: $11.95B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.